|
Jun 17
|
Anne Wojcicki wins bid to buy back 23andMe for $305M
|
|
Jun 17
|
Anne Wojcicki's bid to buy back 23andMe may not end legal fight over DNA customer data
|
|
Jun 16
|
Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer
|
|
Jun 16
|
EHA 2025: Regeneron’s Lynozyfic with Amgen’s Kyprolis combo emerges for R/R MM
|
|
Jun 16
|
Regeneron Pharmaceuticals Loses Bid as 23andMe to Sell Core Assets to TTAM for $305 Million
|
|
Jun 15
|
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
|
|
Jun 15
|
These Were the 2 Worst-Performing Stocks in the S&P 500 in May 2025
|
|
Jun 15
|
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
|
|
Jun 14
|
Anne Wojcicki’s nonprofit reaches deal to acquire 23andMe
|
|
Jun 13
|
Anne Wojcicki Wins Bidding for 23andMe
|
|
Jun 13
|
23andMe's founder Anne Wojcicki wins bid for bankrupt DNA testing firm
|
|
Jun 13
|
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
|
|
Jun 13
|
These Were the 2 Worst-Performing Stocks in the Nasdaq-100 in May 2025
|
|
Jun 12
|
Consumer sentiment, Regeneron meeting, Apple WWDC: What to Watch
|
|
Jun 12
|
Is This Stock a Buy After Acquiring a Potential Zepbound Competitor?
|
|
Jun 12
|
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target
|
|
Jun 10
|
Stock Market News for Jun 10, 2025
|
|
Jun 9
|
Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season
|
|
Jun 9
|
Regeneron and Sanofi’s dupilumab shows promise in AD trial
|
|
Jun 9
|
As tech leads, which stocks have outperformed since April 8 rout?
|